A Review on Pathogenesis and Treatment of Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a multisystem, chronic inflammatory disease with autoimmune characteristics that has no known ethology. It is characterised by distinctive joint abnormalities and a higher death rate. Several cytokines, particularly interleukin-1 and tumour necrosis factor-a, are significantly involved in the induction and maintenance of the chronic inflammatory process of the joints in RA as well as in the systemic manifestations of the disease, suggesting that a number of factors contribute to the pathogenesis of this serious disease. The degeneration of the rheumatoid joint may also be influenced by other elements including metalloproteinase and reactive oxygen species. Despite the best usage of existing ant rheumatic drugs, many RA patients experience discomfort, significant functional loss, and early mortality. This is because present therapies for RA are insufficient since they only partially manage established RA. The necessity for novel therapeutic regimens with the potential to effectively regulate the inflammatory process in the rheumatoid joint and to generate long-term remission or perhaps cure is underscored by the recent statistics about the prognosis of RA with the use of the present medicines. The primary treatment objective is to regulate the production and activity of the factors involved in the pathophysiology of the illness. Neutralising one or a few of the many variables that contribute to the pathophysiology of RA may not have much of an impact. Because it inhibits the majority of the major factors involved in the pathophysiology of the illness rather than being restricted by its inhibitory actions to a single component, interleukin 4 may be a very promising drug for a successful therapy of RA in this regard. Controlled long-term clinical trials should be conducted to demonstrate the validity and efficacy of this potential method, even if recent studies clearly support it when used with interleukin-4